Medpace Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Medpace Holdings, Inc. on July 3, 2024, covering events occurring on June 28, 2024. The filing addresses changes to the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Ashley M. Keating resigned from the Board of Directors, effective June 30, 2024. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Election: The Board unanimously elected Dr. Dani S. Zander to fill the Class III director vacancy, effective July 1, 2024. Her term will last until the 2025 Annual Meeting of Stockholders.
- Committee Appointment: Dr. Zander was appointed to the Nominating and Governance Committee, effective July 1, 2024.
Outlook, Risks, and Unusual Items
Compensatory Arrangements: Dr. Zander will participate in the standard compensation program for non-employee directors. On July 1, 2024, she was granted an equity award consisting of an option to purchase 824 shares of common stock. The exercise price equals the closing price on July 1, 2024, with a seven-year term. The Company also entered into a standard indemnification agreement with Dr. Zander.
Background: Dr. Zander is the MacKenzie Chair of the Department of Pathology and Laboratory Medicine at the University of Cincinnati and Chief of Pathology for UC Health. She has extensive experience in lung pathology, academic leadership, and editorial roles.
Key Facts for Investor Verification
- Confirm the effective dates of Ashley M. Keating's resignation (June 30, 2024) and Dr. Dani S. Zander's appointment (July 1, 2024).
- Verify the specific terms of the equity award granted to Dr. Zander (824 shares, 7-year term).
- Review Dr. Zander's full biographical details and potential conflicts of interest given her academic and medical leadership roles.
- Check subsequent filings for any further changes to the Board composition or committee assignments.